Safety Profile & Chemical Identity of Melanotan-2 Data from peer-reviewed publications and supplier datasheets Melanotan-2 Chemical Identity Synthetic cyclic heptapeptide analog of -MSH with lactam bridge Asp-Lys Melanotan-2 Documented Tolerance Profile Data from pilot clinical studies and peer-reviewed case reports Published clinical and preclinical data Four peer-reviewed trials and case reports Phase I pilot 1996, Wessells 1998-2000, case reports 2011-2014 2/3 Subjects with measurable pigmentation after 5 low doses of 0,01-0,03 mg/kg SC Doses studied (mg/kg SC) MC4R+ Central erectile function effects documented in double-blind crossover Evaluation method 20 years Cumulative review of Melanotan-I and Melanotan-II development since the University of Arizona Documented steps Case report Melanoma reported after Melanotan-2 injections + use of UV tanning beds Clinical context 3 generations Pharmacological evolution: MT2 (pan-MCR) bremelanotide (MC4R pref.) afamelanotide (MC1R selective) Receptor selectivity Important Notice Search Only Not intended for human consumption
SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis
Retatrutide is an investigational triple agonist peptide currently under clinical development, targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously
Progress photos: Same lighting, same angles, same clothing (or lack thereof)
Contrave uses a 4-week dose escalation to reach the full maintenance dose
It fuels the citric acid cycle
